FDx Advisors Inc. Decreases Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

FDx Advisors Inc. lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 56.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,613 shares of the medical equipment provider's stock after selling 2,131 shares during the quarter. FDx Advisors Inc.'s holdings in Intuitive Surgical were worth $644,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ISRG. Vanguard Group Inc. boosted its position in Intuitive Surgical by 0.7% during the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider's stock valued at $8,730,184,000 after buying an additional 196,316 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Intuitive Surgical by 1.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider's stock valued at $5,726,102,000 after buying an additional 272,741 shares during the period. Edgewood Management LLC boosted its position in Intuitive Surgical by 7.9% during the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider's stock valued at $1,731,016,000 after buying an additional 374,667 shares during the period. Fisher Asset Management LLC boosted its position in Intuitive Surgical by 2.0% during the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider's stock valued at $1,516,222,000 after buying an additional 88,977 shares during the period. Finally, Jennison Associates LLC boosted its position in Intuitive Surgical by 4.6% during the first quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider's stock valued at $1,791,253,000 after buying an additional 198,483 shares during the period. Institutional investors own 83.64% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Evercore ISI increased their target price on shares of Intuitive Surgical from $385.00 to $425.00 and gave the stock an "in-line" rating in a report on Tuesday, July 2nd. Piper Sandler increased their target price on shares of Intuitive Surgical from $435.00 to $490.00 and gave the stock an "overweight" rating in a report on Tuesday. Citigroup increased their target price on shares of Intuitive Surgical from $462.00 to $512.00 and gave the stock a "buy" rating in a report on Wednesday. Jefferies Financial Group increased their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a "hold" rating in a report on Friday, April 19th. Finally, Stifel Nicolaus raised their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a "buy" rating in a report on Monday, April 8th. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $410.32.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $421.06, for a total value of $589,484.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Robert Desantis sold 239 shares of Intuitive Surgical stock in a transaction on Monday, June 10th. The shares were sold at an average price of $416.60, for a total transaction of $99,567.40. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,293,799.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $421.06, for a total transaction of $589,484.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,956 shares of company stock valued at $6,927,011. Company insiders own 0.80% of the company's stock.

Intuitive Surgical Stock Performance

Shares of ISRG traded down $1.24 on Thursday, hitting $443.50. 1,818,494 shares of the stock traded hands, compared to its average volume of 1,508,481. The company has a market capitalization of $157.31 billion, a PE ratio of 80.05, a P/E/G ratio of 5.74 and a beta of 1.39. The business has a 50 day simple moving average of $415.83 and a 200 day simple moving average of $389.66. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $449.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm's quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.00 earnings per share. On average, equities analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.